Seeking Alpha

Oral drugs for treating hepatitis C from Merck (MRK) and Abbott Labs (ABT) were highly effective...

Oral drugs for treating hepatitis C from Merck (MRK) and Abbott Labs (ABT) were highly effective in Phase II trials. A regimen that included Merck's MK-5172 suppressed the virus in most patients and appears to be better than the company's Victrelis. Merck now intends to conduct new studies, while Abbott has already started Phase III trials of a regimen of three of its treatments - ABT-450, boosting agent ritonavir (ABT-267) and ABT-333.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|